Display options
Cite
Langer SW. Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res. 2014;6:357-63doi: 10.2147/CMAR.S47238.
Langer, S. W. (2014). Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer management and research, 6357-63. https://doi.org/10.2147/CMAR.S47238
Langer, Seppo W. "Dexrazoxane for the treatment of chemotherapy-related side effects." Cancer management and research vol. 6 (2014): 357-63. doi: https://doi.org/10.2147/CMAR.S47238
Langer SW. Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res. 2014 Sep 15;6:357-63. doi: 10.2147/CMAR.S47238. eCollection 2014. PMID: 25246808; PMCID: PMC4168851.
Copy Download .nbib Format: NLM
Share it on

Cancer Manag Res. 2014 Sep 15;6:357-63. doi: 10.2147/CMAR.S47238. eCollection 2014.

Dexrazoxane for the treatment of chemotherapy-related side effects.

Cancer management and research

Seppo W Langer

Affiliations

  1. Thoracic and Neuroendocrine Section, Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark.

PMID: 25246808 PMCID: PMC4168851 DOI: 10.2147/CMAR.S47238

Abstract

For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.

Keywords: anthracyclines; cardiomyopathy; extravasation

References

  1. Prog Nucleic Acid Res Mol Biol. 2000;64:221-53 - PubMed
  2. Tsitologiia. 1997;39(10):928-37 - PubMed
  3. Cancer Treat Rep. 1984 Jun;68(6):895-6 - PubMed
  4. J Clin Oncol. 1992 Jan;10(1):117-27 - PubMed
  5. Drugs Exp Clin Res. 1988;14(9):563-70 - PubMed
  6. Cancer Treat Rep. 1986 Jun;70(6):703-9 - PubMed
  7. Cancer Prev Control. 1999 Apr;3(2):145-59 - PubMed
  8. Ann Oncol. 2001 Mar;12(3):405-10 - PubMed
  9. Am J Surg. 1979 Mar;137(3):408-12 - PubMed
  10. J Hand Surg Am. 1983 Jan;8(1):32-8 - PubMed
  11. N Engl J Med. 1988 Sep 22;319(12):745-52 - PubMed
  12. J Clin Oncol. 2000 Aug;18(16):3064 - PubMed
  13. Biochem Pharmacol. 1999 Apr 1;57(7):727-41 - PubMed
  14. Ann Oncol. 2007 Mar;18(3):546-50 - PubMed
  15. Tumori. 2009 May-Jun;95(3):273-82 - PubMed
  16. J Clin Oncol. 2009 Jan 1;27(1):127-45 - PubMed
  17. Semin Oncol. 1998 Aug;25(4 Suppl 10):15-21 - PubMed
  18. Biochem Pharmacol. 1988 Oct 1;37(19):3663-9 - PubMed
  19. Circ Res. 2010 Jan 8;106(1):19-20 - PubMed
  20. J Clin Oncol. 1996 Feb;14(2):362-72 - PubMed
  21. Biochem Pharmacol. 1995 Sep 28;50(7):953-8 - PubMed
  22. Cancer. 1981 Apr 15;47(8):1959-62 - PubMed
  23. Toxicol Appl Pharmacol. 1974 Mar;27(3):517-26 - PubMed
  24. Cancer. 1977 Nov;40(5):2053-6 - PubMed
  25. Ann Oncol. 2006 Apr;17(4):614-22 - PubMed
  26. Am J Med. 1977 Feb;62(2):200-8 - PubMed
  27. J Clin Oncol. 1998 Jan;16(1):86-92 - PubMed
  28. Curr Med Chem. 1998 Feb;5(1):1-28 - PubMed
  29. Invest New Drugs. 1987;5(2):187-98 - PubMed
  30. Oncol Nurs Forum. 1995 May;22(4):675-80 - PubMed
  31. J Clin Oncol. 1997 Apr;15(4):1318-32 - PubMed
  32. J Clin Oncol. 1997 Apr;15(4):1333-40 - PubMed
  33. Nat Rev Cancer. 2009 May;9(5):338-50 - PubMed
  34. Ann Plast Surg. 1987 Oct;19(4):323-9 - PubMed
  35. Acta Oncol. 2001;40(4):541-2 - PubMed
  36. Nature. 1969 Apr 26;222(5191):384-5 - PubMed
  37. Eur J Cancer. 2013 Sep;49(13):2900-9 - PubMed
  38. Leukemia. 2010 Feb;24(2):355-70 - PubMed
  39. Cancer Chemother Pharmacol. 2006 Jan;57(1):125-8 - PubMed
  40. Int J Clin Pract. 2013 Mar;67(3):244-9 - PubMed
  41. Cancer. 1976 Sep;38(3):1087-94 - PubMed
  42. Lancet Oncol. 2004 May;5(5):320-1 - PubMed
  43. Support Care Cancer. 2012 May;20(5):1109-12 - PubMed
  44. Circulation. 2010 Jan 19;121(2):276-92 - PubMed
  45. J Clin Oncol. 1989 Jul;7(7):947-58 - PubMed
  46. Cancer Treat Rep. 1981 Mar-Apr;65(3-4):249-52 - PubMed
  47. Am J Cardiovasc Drugs. 2005;5(4):233-43 - PubMed
  48. Clin Cancer Res. 2000 Sep;6(9):3680-6 - PubMed
  49. J Clin Oncol. 2008 Mar 1;26(7):1106-11 - PubMed
  50. Cancer Treat Rep. 1981 May-Jun;65(5-6):459-63 - PubMed
  51. J Clin Oncol. 2001 Jan 1;19(1):191-6 - PubMed
  52. Oncologist. 2010;15(11):1220-6 - PubMed
  53. Toxicology. 2010 Feb 28;269(1):67-72 - PubMed
  54. Lab Invest. 1983 Jul;49(1):69-77 - PubMed
  55. J Clin Oncol. 1990 Nov;8(11):1806-10 - PubMed
  56. J Clin Oncol. 2007 Feb 10;25(5):493-500 - PubMed
  57. Br Med J. 1969 Mar 29;1(5647):822-4 - PubMed
  58. N Engl J Med. 2004 Jul 8;351(2):145-53 - PubMed
  59. J Clin Oncol. 1996 Dec;14(12):3112-20 - PubMed
  60. Scand J Plast Reconstr Surg Hand Surg. 2003;37(3):174-5 - PubMed
  61. N Engl J Med. 1991 Mar 21;324(12):808-15 - PubMed
  62. Cancer Treat Rep. 1979 Jan;63(1):89-92 - PubMed
  63. Ther Clin Risk Manag. 2009 Apr;5(2):361-6 - PubMed

Publication Types